after cessation of prostacyclin infusion in sheep Angiotensin II mediates systemic rebound hypertension

[1]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[2]  V. Fuster,et al.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. , 1993, British heart journal.

[3]  A. Wood,et al.  β‐Adrenergic receptor—mediated release of norepinephrine in the human forearm , 1993, Clinical pharmacology and therapeutics.

[4]  J. Newman,et al.  Adrenergic modulation of the pulmonary circulation during strenuous exercise in sheep. , 1993, The American review of respiratory disease.

[5]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[6]  A. Wood,et al.  Optimization of high-performance liquid chromatographic assay for catecholamines. Determination of optimal mobile phase composition and elimination of species-dependent differences in extraction recovery of 3,4-dihydroxybenzylamine. , 1992, Journal of chromatography.

[7]  H. Sinzinger,et al.  A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease. , 1990, Prostaglandins.

[8]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[9]  D. Badesch,et al.  Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. , 1989, American journal of respiratory cell and molecular biology.

[10]  J. Wallwork,et al.  Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. , 1989, Chest.

[11]  A. Dubrow,et al.  Epoprostenol (PGI2, Prostacyclin) During High‐Risk Hemodialysis: Preventing Further Bleeding Complications , 1988, Journal of clinical pharmacology.

[12]  B. Meyrick,et al.  Continuous air embolization into sheep causes sustained pulmonary hypertension and increased pulmonary vasoreactivity. , 1988, The American journal of pathology.

[13]  T. Higenbottam.  The place of prostacyclin in the clinical management of primary pulmonary hypertension. , 1987, The American review of respiratory disease.

[14]  T. Higenbottam,et al.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). , 1987, British heart journal.

[15]  I. Macdonald,et al.  The effect of adrenaline upon cardiovascular and metabolic functions in man. , 1985, Clinical science.

[16]  Y. Miura,et al.  The effects of epinephrine on norepinephrine release in essential hypertension. , 1985, Hypertension.

[17]  T. Higenbottam,et al.  LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) , 1984, The Lancet.

[18]  M. Brown,et al.  Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. , 1983, The American journal of cardiology.

[19]  D. Betteridge,et al.  Differences in the stability of prostacyclin in human, rabbit and rat plasma. , 1983, Prostaglandins, leukotrienes, and medicine.

[20]  K. Rådegran,et al.  Prostacyclin infusion during extracorporeal circulation foe coronary bypass. , 1982, The Journal of thoracic and cardiovascular surgery.

[21]  M. Brown,et al.  IS ADRENALINE THE CAUSE OF ESSENTIAL HYPERTENSION? , 1981, The Lancet.

[22]  C. Forbes,et al.  Successful Treatment of Raynaud's Syndrome with Prostacyclin , 1981, Thrombosis and Haemostasis.

[23]  A. Szczeklik,et al.  Prostacyclin therapy in peripheral arterial disease. , 1980, Thrombosis research.

[24]  G. Fitzgerald,et al.  Prostacyclin stimulates the renin angiotensin aldosterone system in man. , 1979, The Journal of clinical endocrinology and metabolism.

[25]  C. Sussman,et al.  Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. , 1979, The Journal of laboratory and clinical medicine.

[26]  B. Christman,et al.  Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. , 1996, Journal of applied physiology.

[27]  J. Floras,et al.  Epinephrine and the genesis of hypertension. , 1992, Hypertension.

[28]  R. Mellins,et al.  Relation of arachidonate metabolites to abnormal control of the pulmonary circulation in a child. , 1985, The American review of respiratory disease.

[29]  H. Majewski,et al.  Prejunctional ß-adrenoceptors and hypertension: a hypothesis revisited , 1984 .

[30]  C. Patrono,et al.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man. , 1982, The Journal of clinical investigation.

[31]  R. Olson,et al.  Prostaglandins mediate the macula densa stimulated renin release. , 1980, Advances in prostaglandin and thromboxane research.